ARTELO BIOSCIENCES, INC. (ARTL) - Dilution Analysis

10-Q filing | 2.3M shares outstanding

S-1 filing: This prospectus relates to the offer and resale of common stock, pre-funded warrants, and common warrants by selling stockholders.

8-K filing: Artelo Biosciences, Inc. completed a private placement offering of common stock, pre-funded warrants, and common warrants for gross proceeds of $10,996,902.70. ($11.0M proceeds)

S-1/A filing: The filing relates to an offering of common stock and pre-funded warrants, as well as shares of common stock issuable upon exercise of pre-funded warrants and placement agent warrants.

S-1/A filing: The filing is an S-1/A amendment for an offering of common stock and pre-funded warrants to purchase common stock.

S-1 filing: This prospectus relates to the offer and resale of up to an aggregate of 899,972 shares of common stock by the selling securityholders.

8-K filing: Artelo Biosciences, Inc. issued convertible notes and warrants to certain investors, with directors and officers also participating in the offering.

8-K filing: Artelo Biosciences, Inc. completed an underwritten offering of 441,210 shares of common stock at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of common stock at $4.399 per Pre-funded Warrant, for gross proceeds of approximately $2 million. ($2.0M proceeds)

10-Q filing | 0.7M shares outstanding

8-K filing: Artelo Biosciences, Inc. entered into a Consulting Agreement with ABK Labs, Inc. to issue warrants to purchase up to 55,000 shares of the Company's common stock at an exercise price of $10.20 per share.

8-K filing: Artelo Biosciences, Inc. entered into a Securities Purchase Agreement to issue and sell shares of common stock, prefunded warrants, and warrants in a private placement, with gross proceeds expected to be approximately $9.475 million.

S-1 filing: This S-1 filing relates to the offer and resale of common stock by selling securityholders, including shares, shares issuable upon exercise of pre-funded warrants, $5.82 warrants, and $10.00 warrants, issued in a private placement.

8-K filing: Artelo Biosciences, Inc. entered into a securities purchase agreement for a private placement of shares of common stock, pre-funded warrants, and warrants, with gross proceeds expected to be approximately $1.425 million. ($1.43M proceeds)

8-K filing: Stock split 1-for-6 | Outstanding: 3,281,000 → 546,667

10-Q filing | 3.3M shares outstanding

10-K filing | 3.2M shares outstanding

10-Q filing | 3.2M shares outstanding

10-Q filing | 3.2M shares outstanding

10-Q filing | 3.2M shares outstanding

10-K filing | 2.9M shares outstanding

10-Q filing | 2.9M shares outstanding

10-Q filing | 2.9M shares outstanding

S-3 filing: Artelo Biosciences, Inc. is filing an S-3 to offer common stock, preferred stock, and debt securities up to an aggregate amount of $75,000,000.

10-Q filing | 2.9M shares outstanding

10-K filing | 1.6M shares outstanding

10-Q filing | 2.9M shares outstanding

8-K filing: Stock split 1-for-15 | Outstanding: 42,593,981 → 2,839,600

10-Q filing | 42.6M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale of up to 15,000,000 shares of common stock of Artelo Biosciences, Inc. by Lincoln Park Capital Fund, LLC.

8-K filing: Artelo Biosciences entered into a purchase agreement with Lincoln Park Capital Fund, LLC for the purchase of up to $20.0 million worth of the Company's common stock over a 36-month period, and issued 292,968 commitment shares to Lincoln Park as consideration for entering the agreement.

10-Q filing | 42.3M shares outstanding

10-Q filing | 42.3M shares outstanding

10-K filing | 5.0M shares outstanding

10-Q filing | 24.5M shares outstanding

10-Q filing | 23.1M shares outstanding

POS AM filing: This POS AM filing details several issuances of common stock through Series D and E offerings, issuances for services, and issuances to directors.

POS AM filing: This is a POS AM filing including information on Series D and E offerings, issuances to Blackrock Ventures and NEOMED, and shares issued to Directors.

POS AM filing: This filing relates to the registration of securities and includes information about previous issuances of common stock.

10-Q filing | 15.7M shares outstanding

10-K filing | 15.1M shares outstanding

8-K filing: Artelo Biosciences, Inc. closed a public offering of 10,120,000 shares of common stock and warrants to purchase 10,120,000 shares of common stock at a price of $0.75 per unit, resulting in net proceeds of approximately $6.58 million.

S-1/A filing: This is an S-1/A filing from 2020-10-08 which discusses multiple prior offerings of common stock and warrants.

S-1/A filing: This is an S-1/A filing including exhibits such as the underwriting agreement, warrants, articles of incorporation, bylaws, legal opinions, and various agreements.

S-1/A filing: This is an offering of 6,395,348 Units consisting of an aggregate of 6,395,348 shares of our common stock and 6,395,348 warrants to purchase 6,395,348 shares of our common stock based on a public offering price of $ 0.86 per Unit.

S-1 filing: This is a preliminary prospectus for an offering of units, each consisting of one share of common stock and one warrant to purchase one share of common stock, with Ladenburg Thalmann & Co. Inc. as the sole book-running manager.

10-Q filing | 4.5M shares outstanding

10-Q filing | 3.4M shares outstanding

POS AM filing: This POS AM filing from Artelo Biosciences, Inc. relates to the offering of shares of common stock issuable upon the exercise of warrants, originally issued as part of a unit offering, with exercise prices of $6.4575 and $6.765 per share.

S-3 filing: The filing is an S-3 form by Artelo Biosciences, Inc. for a shelf offering of various securities up to an aggregate amount of $100,000,000.

10-Q filing | 3.4M shares outstanding